Bexson Biomedical raises $4.8m in Series A round for subcutaneous ketamine treatment platform
Bexson Biomedical has raised $4.8 million in a Series A financing round for developing a subcutaneous ketamine treatment platform for pain management and mental health disorders. The Series A round was led by Noetic Psychedelic Fund. Michael Franks – a Managing Partner at Noetic Psychedelic Fund said: “We are very excited to support the entire […]